

Company Overview

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference

Jul 19 2021, 7:30 AM EDT

BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock

Jun 23 2021, 8:28 AM EDT

BioXcel Therapeutics Announces Proposed Public Offering of Common Stock

Jun 22 2021, 4:01 PM EDT

Stock Overview

| | |
|------------|-------------------|
| Symbol | BTAI |
| Exchange | Nasdaq |
| Market Cap | 720.79m |
| Last Price | \$25.94 |
| 52-Week | \$25.91 - \$67.74 |

07/22/2021 04:00 PM EDT

Investor Relations

BioXcel Therapeutics, Inc.
Mary Coleman
VP of Investment Relations
T: 475-238-6837

Management Team

Vimal Mehta, Ph.D.

Chief Executive Officer & Founder

Richard I. Steinhart

Chief Financial Officer & Vice President

William P. Kane

Chief Commercial Officer

Frank D. Yocca, Ph.D.

Chief Scientific Officer

Reina Benabou, M.D., Ph.D.

Senior Vice President & Chief Development Officer

Vincent J.O'Neill M.D.

Senior Vice President & Chief Medical Officer

Javier Rodriguez

Senior Vice President, Chief Legal Officer, and Corporate Secretary

BioXcel Therapeutics, Inc.

555 Long Wharf Drive
12th Floor
New Haven, CT 06511
United States

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.